Three Blackwell Burke P.A. Attorneys Listed on the Benchmark Litigation 2017 “Under 40 Hotlist”
The Benchmark Litigation “2017 40 under 40 List” honors the achievements of the nation’s most accomplished legal partners of the age of forty or younger. Blackwell Burke P.A. is proud of its three attorneys receiving this recognition. Gerardo “Jerry” Alcazar’s practice includes products liability, commercial litigation, and other complex matters often involving high stakes litigation. […]
Blackwell Burke P.A. Secures Dismissal of Putative, National Window Class Action
Blackwell Burke P.A. recently secured a complete defense victory on behalf of a national window manufacturer. Plaintiffs alleged negligent product design and manufacture, breach of express and implied warranties, and fraud, on behalf of a putative, national consumer class in a Minnesota federal district court. The lawsuit arose from plaintiffs’ contention that the insulated glass […]
Benchmark Litigation Presents Blackwell Burke P.A. with Minnesota Firm of the Year Award
On February 16, 2017, Blackwell Burke was honored as the “Minnesota Firm of the Year” at the Benchmark Litigation 2017 US awards. The event, held at the Essex House Hotel in New York City, recognized the top litigation firms in all 50 states. Partner Peter Goss attended the Benchmark Litigation 2017 US Awards ceremony and […]
Peter Goss Analyzes New Jersey Summary Judgment Order in Talc Suits against Johnson & Johnson
Peter Goss was quoted in Law360’s analysis of a recent New Jersey trial court ruling in the Johnson & Johnson talc litigation. The order excluded the plaintiffs’ experts’ testimony and dismissed the claims of two women who alleged that exposure to bath talc caused their ovarian cancer. (“J&J Talc Suits Show Evidence Standards Vary Among […]
Peter Goss Comments on Emerging Appellate Split on Generic Drug Preemption
Peter Goss commented for Law360 on a recent ruling by the New Jersey Supreme Court finding no federal preemption where the generic drug manufacturer’s label for metoclopramide (Reglan) did not match that of the brand. (“NJ Reglan Ruling Widens Generic Label Preemption Split,” available with subscription here.) Goss noted that the decision conflicted with Fifth and Sixth […]
Peter Goss Discusses FDA Approval of New Implant for Opioid Addiction Treatment
Peter J. Goss was interviewed by Law360 for an article analyzing the FDA’s recent approval of an implantable version of an opioid addiction drug, Probuphine. (“FDA’s Opioid Implant Nod Shows Pressure To Curb Addiction,” available to Law360 subscribers here.) Goss noted that the FDA has been under pressure to curb the opioid abuse epidemic, and that the approval […]
BLACKWELL BURKE P. A. EARNS HIGH MARKS IN U.S. NEWS & WORLD REPORT and BEST LAWYERS IN AMERICA© “BEST LAW FIRMS” LIST
Blackwell Burke P.A. has been included on the 2016 U.S. News & World Report and Best Lawyers Best Law Firms list with a ranking of Metropolitan Tier 1 for Products Liability Litigation – Defendant, and a Tier 2 ranking under Mass Tort Litigation/Class Actions – Defendants. The U.S. News – Best Lawyers “Best Law Firms” […]
BLACKWELL BURKE RANKED ‘HIGHLY RECOMMENDED’ AND SIX FIRM ATTORNEYS NAMED ‘MINNESOTA LITIGATION STARS’ OR ‘FUTURE STARS’ BY BENCHMARK LITIGATION
Blackwell Burke P.A. has been ranked as “Highly Recommended” in the 2016 Edition of Benchmark Litigation, one of just eight Minnesota firms to receive that recognition. Firm Founder and CEO Jerry Blackwell, partners Corey Gordon, Peter Goss, Benjamin Hulse, and special counsel Mike Hatch have all been named Minnesota Litigation Stars. Partner Mary Young was […]
Peter Goss Shares Advice on Avoiding Attorney-Client Privilege Blunders
Peter J. Goss recently commented for a Law360 article entitled “The 3 Biggest Blunders With Attorney-Client Privilege.” Goss cautioned that written memoranda containing advice on changes to business practices are often difficult or impossible to “claw back” after inadvertent disclosure. These memoranda can prove troublesome when they recommend a course of action that the company […]
Peter J. Goss Discusses $71 Million Amgen Off-Label Marketing Settlement in Law360
Law360 quoted Peter J. Goss in its analysis of the recent $71 million settlement between Amgen and the Attorneys General of 48 states and the District of Columbia over alleged off-label marketing of two of the company’s blockbuster drugs, Enbrel and Aranesp. Goss commented that the settlement was driven by a December 2012 settlement of […]